Guggulsterones: A Comprehensive Reference
1. Identity and Chemical Characterization
Botanical Source and Nomenclature
Guggulsterone (pregna-4,17-diene-3,16-dione; C21H28O2) is a phytosterol isolated from the gum resin of the tree Commiphora wightii (Arnott.) Bhand., also classified as Commiphora mukul Engl., and is regarded as the primary bioactive constituent responsible for many of the properties of guggul. The plant belongs to the Burseraceae family and is endemic to the semiarid climates of Pakistan and West India. Common names for the tree include Indian bdellium-tree, gugal, guggal, guggul, gugul, and mukul myrrh tree; the species is native to western India, from where it was introduced westward to southern Pakistan and the Middle East.
Commiphora wightii grows as a shrub or small tree reaching a maximum height of 4 meters, with thin papery bark and thorny branches. The wild occurrence of this species is restricted mainly to the dry regions of Rajasthan and Gujarat States of India, and the bordering regions of Pakistan. Due to overharvesting for traditional medicine, Commiphora wightii has become endangered and is listed on the IUCN Red List of threatened species.
Chemical Structure and Isomers
Guggulsterone possesses the molecular formula C21H28O2 and is systematically named pregna-4,17(20)-diene-3,16-dione. It exhibits a characteristic pregnadiene dione structure, consisting of a four-ring steroidal backbone fused in a cyclopentanoperhydrophenanthrene configuration. The molecular weight is 312.45 g/mol.
Guggulsterones exist as two stereoisomers differing only in cis-trans isomerism at position C-17, namely (E)-guggulsterone and (Z)-guggulsterone. The two major geometrical isomers at C20 are known as E-guggulsterone (E-4,17(20)-trans-pregnadiene-3,16-dione) and Z-guggulsterone (Z-4,17(20)-cis-pregnadiene-3,16-dione). The E-isomer possesses a trans arrangement of the substituents across the exocyclic double bond, resulting in a more extended conformation, whereas the Z-isomer features a cis configuration that introduces greater steric crowding.
The Z- and E-stereoisomers of guggulsterones are present in guggul resin at a concentration of approximately 4.0–6.0%. Both isomers have significant pharmacological actions and pharmacokinetic behavior.
The Parent Resin: Guggul and Gugulipid
Guggul is the dry gum resin obtained from incisions in the bark of the Commiphora mukul tree; the gum contains minerals, resin, volatile oils, sterols, ferulates, flavones, sterones, and other chemical constituents. C. mukul is a hardy tree/shrub highly sought for its oleoresin (gum guggul), which is further processed by solvent extraction to produce gum guggul extract (GGE). The trees are 4–6 feet tall, ash-colored, free of foliage throughout most of the year, and slow growing, requiring 5–6 years to attain the maturity necessary for harvesting of oleoresin.
Several pharmacologically active components have been identified in the plant, including guggulsterone (E- and Z-stereoisomers) and gugulipid, both found in the ethyl acetate extract of the plant. More than 300 types of secondary metabolites have been identified through phytochemical studies of this genus. A lipophilic extract prepared from the resin contains many classes of compounds, among which lignans, terpenes, and ketosteroids named guggulsterones. A triterpene, myrrhanol A, has also been described to have potent anti-inflammatory effects.
Commercial Forms and Standardization
In the Indian market, more than fifty formulations of guggul have been introduced by well-known brands including Himalaya, Patanjali, and Baidyanath Pharmaceuticals. Guggul is commercially available in various forms including capsules, tablets, and extracts. It can be found in health food stores, online retailers, and specialty Ayurvedic medicine suppliers. The gum can also be purchased in a loosely packed form called dhoop, which is traditional Indian incense burned over hot coals.
High-performance liquid chromatography and thin-layer chromatography methods for standardization have been described, and adulterants have been found in commercial preparations. A critical quality concern relates to commercial product accuracy: liquid chromatography has shown that some commercial over-the-counter products contain less than—or none of—their claimed guggulsterone content.
2. Traditional and Historical Use
Ayurvedic Medicine
The history of guggul goes as far back as 1700 BC. The ancient script on medicine and surgery, Sushrut Samhita, describes that guggul when taken orally can cure internal tumors, malignant sores, obesity, liver dysfunction, intestinal worms, leucoderma, sinus, and edema. It is also used as an Ayurvedic medicine for the prevention and treatment of various other diseases such as inflammatory bowel disease (IBD), ulcers, arthritis, cardiovascular diseases, and diabetes.
The extract of gum guggul, called gugulipid, guggulipid, or guglipid, has been used in Unani and Ayurvedic medicine for nearly 3,000 years in India. Guggul has been used in the Indian traditional system for thousands of years to manage inflammation, gout, rheumatism, arthritis, obesity, and lipid metabolism disorders. The Sanskrit name guggulu is said to mean "protects from disease," underscoring the plant's central importance in the tradition.
This plant is widely used as traditional medicine in the Ayurveda and Unani systems of medicine. In traditional Chinese medicine, Ayurvedic medicine, and traditional Arabic medicine, myrrh is regarded as an important medicinal material, widely used in the treatment of trauma, arthritis, hyperlipidemia, and other diseases.
Traditional Preparations and Formulations
In traditional practice, guggul is often combined with other herbs to create synergistic formulations. The resin can be processed into various forms including tablets, powders, and medicated oils depending on the intended therapeutic application. Guggulu's powerful detoxifying and rejuvenating qualities can enhance the benefits of other herbs when used in combination, and as such it is the basis for an entire class of traditional Ayurvedic formulas known as guggulus.
From an Ayurvedic perspective, guggul is held to balance all three doshas of vata, pitta, and kapha, though it is especially renowned for alleviating vata aggravations. According to Ayurvedic principles, guggul is believed to balance the doshas and support the body's natural healing processes; it is considered particularly effective for conditions related to ama (toxins) and for supporting metabolism and circulation.
Regulatory History in India
In 1966, the first medical studies in animals were conducted, and in 1986, guggal was approved for marketing in India as a hypolipidemic drug. Since 1988, guggulipid has been marketed in India as a hypolipidemic agent and is still prescribed for the treatment of hyperlipidemia.
3. Key Constituents and Mechanisms of Action
The Farnesoid X Receptor (FXR) Pathway
It has been established that guggulsterone is a highly efficacious antagonist of farnesoid-X-receptor (FXR), a key transcriptional regulator for the maintenance of cholesterol and bile acid homeostasis. It has been proposed that inhibition of FXR activation is the basis for the cholesterol-lowering activity of guggulsterone.
Conversion of cholesterol to bile acids in the liver is initiated by the rate-limiting enzyme cholesterol 7α-hydroxylase (CYP7A1), and excretion of bile acids from the liver is mediated by the bile salt export pump (BSEP). The expression of CYP7A1 and BSEP is coordinately regulated by a negative feedback and positive feed-forward mechanism, respectively, through bile acid-mediated activation of FXR. It is well established that guggulsterone is an FXR antagonist and down-regulates FXR target genes.
A study showed that guggulsterone activates the bile salt export pump (BSEP), an efflux transporter which removes cholesterol metabolites and bile acids from the liver; such up-regulation of BSEP expression by guggulsterone proposes another possible mechanism for its pronounced lipid-lowering effects. Accordingly, guggulsterone has been proposed as a selective bile acid receptor modulator that regulates expression of a subset of FXR targets.
Nuclear Receptor Interactions Beyond FXR
Studies have found that guggulsterone is a much more potent antagonist for nuclear receptors including the mineralocorticoid receptor (MR), glucocorticoid receptor (GR), and androgen receptor (AR) than for FXR. It has been suggested that these nuclear receptors may be deeply involved in the therapeutic effects, including the hypolipidemic activity, of guggulsterone.
Guggulsterone has no effect on FXR inhibition of the CYP7A1 gene but strongly inhibits the human CYP7A1 gene by activation of the pregnane X receptor (PXR). These results suggest that guggulsterone inhibits bile acid secretion from hepatocytes into bile and activates PXR to inhibit bile acid synthesis in the liver. Reduced conversion of cholesterol and bile acid excretion may lead to an increase of hepatic cholesterol and decrease of intestinal cholesterol absorption, resulting in lowering serum cholesterol.
NF-κB and Inflammatory Signaling
Guggulsterone acts as a nuclear receptor antagonist (FXR) involved in bile acid and cholesterol metabolism, and also controls transcription factors such as NF-κB and STAT3, which are important in inflammatory and cancer processes. NF-κB is a group of inducible transcription factors that control a wide range of genes involved in immunological and inflammatory responses; the modulation of inflammatory responses is a well-known function of NF-κB.
Guggulsterone suppresses the synthesis of proteins associated with anti-apoptotic, cellular function, proliferation and differentiation, thrombotic, metastatic, and chemo-resistant activities in solid tumors.
Anti-Inflammatory Mechanisms
Down-regulation of the expression of inflammatory mediators, including interleukins, transcription factors, cytokines, and hyaluronidase and collagenase enzymes has been demonstrated for extracts of C. mukul. Extracts of the plant have anti-inflammatory action and inhibit carrageenan-induced rat paw edema in animal models. E- and Z-guggulsterones decrease pro-inflammatory cytokines and suppress cyclooxygenase-2 (COX-2) mRNA levels, thereby demonstrating anti-inflammatory and anti-arthritic activity.
Antioxidant Activity
Guggulsterone has antioxidant properties by inhibiting the production of free radicals. Guggulsterone isomers Z and E exhibit potent inhibitory activity against the production of nitric oxide induced by bacterial lipopolysaccharides in macrophages, with IC50 values of 1.1 and 3.3 μM respectively. It is generally accepted that overproduction of nitric oxide is associated with oxidative stress, which is involved in the pathogenesis of cardiovascular diseases or chronic inflammation, diabetes, rheumatoid arthritis, and neurodegenerative diseases.
Androgen Receptor Antagonism
Both stereoisomers of guggulsterone exhibit significant androgen receptor (AR) antagonism, with IC50 values of 660 nM for the E-isomer and 220 nM for the Z-isomer in cell-based transfection assays; they effectively antagonize AR signaling stimulated by R1881 in HEK293 and C2C12 cell lines.
Thyroid Stimulatory Effects (Preclinical)
Administration of guggulsterone was found in preclinical studies to increase thyroid function by enhancing iodine uptake, improving the activities of thyroid peroxidase and protease, and ameliorating hypothyroidism through its ability to increase thyroid hormone in vivo. This evidence, however, comes from animal models, and no large human trials have confirmed the same thyroid-boosting effect.
4. Scientific Evidence by Area of Use
4.1 Lipid-Lowering / Hypercholesterolemia
Background and early studies: Herbal extracts from Commiphora mukul (guggul) have been widely used in Asia as cholesterol-lowering agents. Guggulsterones, the purported bioactive compounds of guggul, have been shown to be potent antagonists of two nuclear hormone receptors involved in cholesterol metabolism, establishing a plausible mechanism of action for the hypolipidemic effects. However, there are no published safety or efficacy data on the use of guggul extracts in Western populations prior to 2003.
In six randomized clinical trials of guggul, the results suggest reductions in total serum cholesterol from 10% to 27% compared with baseline levels. One study showed an increase in HDL cholesterol, and another found that guggul inhibited LDL oxidation. These early trials were predominantly conducted in India. However, most published studies were small and methodologically flawed.
The pivotal Szapary et al. (2003) JAMA trial: In a double-blind, randomized, placebo-controlled trial, Szapary and colleagues studied the short-term safety and efficacy of guggulipid as a cholesterol-lowering agent in a western population of 103 healthy adults. Patients were randomized to receive placebo, 3,000 mg daily of 2.5% standardized guggulipid (standard-dose), or 6,000 mg daily of 2.5% standardized guggulipid (high-dose); each 1,000-mg tablet was tested for purity and found to contain at least 21 mg of guggulsterones.
In this first randomized clinical trial of guggulipid conducted outside of India, neither a commonly used dose nor a high dose of standardized guggulipid improved any of the measured levels of lipoproteins in this large group of patients with moderate hypercholesterolemia eating a Western diet. Despite plausible mechanisms of action, guggulipid did not appear to improve levels of serum cholesterol over the short term in this population of adults with hypercholesterolemia, and might in fact raise levels of LDL-C. No significant changes in total cholesterol, HDL, or triglycerides were measured.
In humans, studies on whether guggul can lower cholesterol levels are mixed; one study suggests it may actually raise cholesterol levels. The effects of guggulipid in patients with high cholesterol are not clear, with some studies finding cholesterol-lowering effects and other research suggesting no benefits; at this time, there is not enough scientific evidence to support the use of guggul for any medical condition.
Animal data: Guggulipid treatment in rats lowered serum triglyceride and raised serum high-density lipoprotein levels. Mice fed guggul had reduced cholesterol levels compared with mice on normal diets. These preclinical findings have not been reliably replicated in well-designed human trials.
Overall evidence strength: Mixed to weak in humans. The body of evidence contains methodologically heterogeneous studies with conflicting results; the most rigorously designed RCT conducted in a Western population found no benefit and a possible adverse effect on LDL-C.
4.2 Inflammation and Arthritis
Guggul was as effective as phenylbutazone and ibuprofen in animal models of acute and chronic inflammation. In mice with induced colitis, guggulsterone decreased the severity of the inflammatory disease. In rats with induced uveitis, guggulsterone demonstrated a protective effect against inflammatory mediators.
Human / clinical evidence: A clinical study evaluating a traditional guggul-based preparation in patients with knee osteoarthritis found significant pain reduction over 84 days of treatment. Pain scores on a standard 10-point scale dropped from an average of 6.71 at baseline to 3.91 at the end of treatment, and continued improving to 3.30 at follow-up. A more detailed pain assessment showed scores cut roughly in half, from 10.31 to 5.09.
Guggulsterone has demonstrated higher anti-inflammatory activities with what are described as minimal side effects, and has been explored for the treatment of diseases such as osteoarthritis, rheumatoid arthritis, and gout.
Overall evidence strength: Preliminary. Pre-clinical evidence is robust. Human clinical evidence is encouraging but limited to small studies. Larger, well-controlled trials are required.
4.3 Inflammatory Bowel Disease (IBD)
Guggulsterone can be considered for the treatment of inflammatory bowel disease, a disease characterized by chronic inflammation and damage in the gastrointestinal tract. In various preclinical studies, it inhibited NF-κB, an important pathway in the pathophysiology of IBD. NF-κB plays an important role in the pathogenesis of IBD; inflamed colonic tissues from IBD patients have constitutive NF-κB activation. Immunosuppressive medications commonly used to treat patients with chronic intestinal inflammation, such as IL-10, sulfasalazine, cyclosporin A, and glucocorticoids, block NF-κB activation. The persistence of NF-κB activation in individuals with active IBD suggests that NF-κB activity modulation is a promising therapeutic target.
Overall evidence strength: Preclinical only. Available evidence is limited to in vitro and animal models; human clinical trials in IBD have not been published as of the available evidence base.
4.4 Acne (Nodulocystic)
One small study has shown guggulsterone to be as effective as tetracycline in the treatment of nodulocystic acne, and in vitro antibacterial effects have been described.
A small clinical trial compared guggul head-to-head with tetracycline in 20 patients with severe nodulocystic acne. Over three months, guggul reduced inflammatory lesions by 68%, while tetracycline achieved a 65.2% reduction. The difference was not statistically significant, meaning the two treatments performed essentially equally.
Overall evidence strength: Preliminary positive. A single small clinical trial demonstrated non-inferiority to a standard antibiotic treatment. The study was small, limiting the certainty of conclusions. Replication in larger trials is required.
4.5 Thyroid Function
In preclinical models, guggulsterone was found to increase thyroid function by enhancing iodine uptake, improving the activities of thyroid peroxidase and protease, and ameliorating hypothyroidism through its ability to increase thyroid hormone in vivo. Some people with sluggish thyroid function are drawn to guggul supplements, but this evidence comes from animal models, and no large human trials have confirmed the same thyroid-boosting effect.
Overall evidence strength: Animal/preclinical only. No adequately powered human RCT has confirmed thyroid-stimulating effects.
4.6 Cancer (Preclinical)
A systematic review found that guggulsterone significantly affected pancreatic cancer, hepatocellular carcinoma, head and neck squamous cell carcinoma, cholangiocarcinoma, esophageal adenocarcinoma, prostate cancer, colon cancer, breast cancer, gastric cancer, colorectal cancer, bladder cancer, glioblastoma, histiocytic leukemia, acute myeloid leukemia, and non-small cell lung cancer by inducing apoptotic pathways, inhibiting cell proliferation, and regulating the expression of genes involved in apoptosis.
In a meta-analysis of 23 studies, 11 reported the apoptotic effect at t=24 h with a pooled odds ratio of 3.984 (95% CI 3.263 to 4.865, p <0.001); 12 studies used guggulsterone for >24 hours with an odds ratio of 11.171 (95% CI 9.148 to 13.643, p <0.001). This systematic review suggested that guggulsterone has apoptotic effects against various cancer types; however, further investigation of its pharmacological activity and mechanism of action should be conducted, and in vivo experiments and clinical trials are required to confirm the anticancer activity.
Guggulsterone not only induces apoptosis in cancer cells and inhibits cell proliferation but may also reduce the cytotoxicity associated with conventional chemotherapeutic agents by sensitizing or causing additive apoptotic effects. Despite extensive study, the conclusive mechanisms responsible for its anticancer effects are still not fully understood; the anticancer action of guggulsterone and its isomers appear to be due to combined effects on proliferation and invasiveness in cancer cells.
In tumor cells, guggulsterone has been reported to induce apoptosis by activating JNK (c-Jun N-terminal kinase) and repressing Akt signaling.
Overall evidence strength: Preclinical only. Substantial in vitro and some in vivo data demonstrate pro-apoptotic activity across multiple cancer cell lines, but there are no published human clinical trials. The anticancer potential is currently investigational.
4.7 Cardiovascular / Platelet Effects
Guggul has been shown to decrease platelet adhesiveness and to increase fibrinolytic activity. Guggul has demonstrated not only an ability to prevent atherosclerosis but also to encourage the regression of pre-existing atherosclerotic plaque in animal studies.
C. mukul in combination with Inula racemosa was studied in 200 patients with ischemic heart disease and found to improve electrocardiogram readings and decrease episodes of dyspnea and chest pain.
This natural product is widely used globally as a natural lipid-lowering agent, although its anti-atherogenic cardiovascular benefit in animal models or humans remains unknown. One animal study's data clearly showed significant adverse effects of gugulipid administration and strongly suggested that the use of this natural product may have deleterious cardiovascular consequences for human health, in particular for patients at high risk for cardiovascular disease.
Overall evidence strength: Preliminary and conflicting. Some animal and small human studies suggest cardiovascular benefit, but at least one animal study raised adverse cardiovascular signals. Human evidence is insufficient.
5. Body Systems and Health Areas Associated with Guggulsterones
- Lipid and cholesterol metabolism: Guggulsterone has a significant role in nutritional metabolism by inhibiting cholesterol production in the liver via FXR and bile acid receptor antagonism; it has been shown to lower LDL cholesterol and triglyceride levels in the blood while increasing HDL cholesterol levels in preclinical studies.
- Inflammatory pathways: The two isomers, Z- and E-guggulsterone, have shown a wide range of in vitro and in vivo pharmacological effects, including anti-proliferation, antioxidant, anti-inflammatory, and antibacterial activity.
- Endocrine / thyroid system: Preclinical evidence for enhancement of iodine uptake and thyroid hormone production; clinical evidence in humans is absent.
- Gastrointestinal tract: Preclinical NF-κB inhibition relevant to IBD and colitis; no human clinical evidence.
- Skin and dermatology: Demonstrated non-inferiority to tetracycline for nodulocystic acne in one small clinical trial.
- Oncology (experimental): Extensive preclinical evidence across multiple cancer lines; no human trials.
- Cardiovascular / hematological: Platelet aggregation inhibition and fibrinolysis demonstrated in vitro and in animal models; human evidence is limited.
- Musculoskeletal: Used to treat various ailments including obesity, osteoarthritis, arthritis, and inflammation.
6. Dosage Forms and Dosages Reported in Studies
Clinical trials are lacking to provide comprehensive dosage guidelines; however, in a US clinical trial of hyperlipidemia, 75 to 150 mg of standardized guggulsterones were administered daily. In a study evaluating the anti-inflammatory effect of guggul, 500 mg of gum guggul was taken three times per day.
In the Szapary et al. JAMA trial, patients were randomized to receive either 3,000 mg daily (standard-dose) or 6,000 mg daily (high-dose) of 2.5% standardized guggulipid.
In one investigation, the therapeutically useful doses of the guggulsterone-enriched fraction were described as comprising between 100 and 1,000 mg/day, while the therapeutic doses of the two guggulsterones (pure) ranged from 10 to 150 mg/day.
In a randomized study, 125 patients were administered gugulipid and 108 were administered clofibrate, resulting in an 11% decrease in blood cholesterol and a 17% decrease in blood triglyceride with gugulipid, compared to 10% and 22%, respectively, with clofibrate.
Guggulipid products are typically standardized to contain 2.5% guggulsterones. The typical daily dose in some formulations is described as providing 100 mg of guggulsterone.
7. Safety Considerations and Drug Interactions
General Safety Profile
No clinical studies have been conducted to evaluate the safety of long-term use of guggul or guggulsterone. Being an herbal product, it is considered safe for short-term use; however, some adverse reactions have been noted in clinical trials including loose stools, mild nausea, and hiccup. Moderate to severe generalized acute eczematous reactions to oral guggul have been reported, and caution may be warranted.
In the Szapary JAMA trial, guggulipid appeared to cause a dermatologic hypersensitivity reaction in some patients. In rats, dogs, and monkeys, no acute, subacute, or chronic toxicity has been reported. No mutagenesis or teratogenicity has been described for gum guggul.
Rhabdomyolysis and Statin-Related Caution
A case report exists of rhabdomyolysis in a patient taking an extract of C. mukul 300 mg three times daily who was previously sensitized (increased creatine kinase) to lipid-lowering statins. A similar case report of increased transaminases exists for a combination preparation containing guggulsterol and red yeast rice extract; however, fungal metabolites found in the red yeast rice extract were suspected to be responsible for the adverse effect because the metabolites are structurally similar to lovastatin. Caution may therefore be warranted in patients who have previously experienced adverse effects to statins.
Hepatotoxicity
In one animal study, gugulipid administration led to liver damage, including hepatomegaly, hepatocellular tumefaction, and elevated plasma ALT levels. A clinical case report adds to evidence that herbal extracts from the guggul tree may not be free of adverse effects, highlighting hepatotoxicity concerns in the context of combination fat-burner products.
Drug Interactions
Consumption of guggulipid (1 g) decreased the bioavailability of the prescribed medications propranolol and diltiazem in healthy male volunteers, indicating a potential for adverse botanical–drug interactions that could alter bioavailability, efficacy, or toxicity of prescription drugs when taken concomitantly with products containing guggul extract.
Guggul may decrease the serum concentration of diltiazem (monitor therapy) and may decrease the serum concentration of propranolol (monitor therapy).
Guggul may increase thyroid hormone activity, so combining it with thyroid medications may cause overcorrection. Guggulsterone interacts with nuclear receptors involved in hormone regulation, and hormonal contraceptives or replacement therapy may be affected.
CYP450 Enzyme Induction
Contrary to prior assumptions, Z-guggulsterone and its metabolites did not induce CYP7A1, but significantly increased bile salt excretion pump activity facilitating cholesterol elimination. Metabolism of Z-guggulsterone was associated with increased activity of multiple CYP450 enzymes, with CYP3A4 being the most active. Induction of CYP3A4 raises the theoretical possibility of interactions with the broad range of drugs metabolized by this enzyme, though this has not been systematically evaluated in humans.
Pregnancy, Lactation, and Special Populations
Information regarding safety and efficacy in pregnancy and lactation is lacking. The human safety profile of the extract has not been well described for children, pregnant or breast-feeding women, or patients with severe hepatic or renal disease.
Product Quality Variability
Guggulipid is a botanical and, like many botanicals, contains potentially hundreds of other molecules, some of them possibly bioactive. Wide variability among currently available commercial brands has been documented. Liquid chromatography analyses have found commercial over-the-counter products that contain less than—or none of—the claimed guggulsterone content, underscoring the importance of standardized, third-party tested products.
References
Volver